rituximab Injection [Rituxan]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Rituximab is a chimeric human-mouse monoclonal antibody directed against the CD20 antigen on B-cells surfaces that leads to the…
This application note describes the use of a nonradioactive, bioluminescent antibody-based complement-dependent cytotoxicity (CDC…
Since the approval of rituximab (Rituxan®) for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) in 1997, nine additional…
Rituximab, an anti-CD20 monoclonal antibody, is licensed for previously treated and previously untreated patients suffering from…
How much better are the newer drugs? In a 2002 study published in the Journal of Clinical Oncology, 80% of patients who received…
The present invention provides a method of treating inflammatory disease or autoimmune disease associated with CD40- expressing…
One of the requirements during the process of manufacturing development of a therapeutic protein is continuous monitoring of…
Rituximab (Mabthera® , Rituxan® ) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20…
Researchers in December launched a new randomized trial for elderly patients with intermediate-grade nonHodgkin 's lymphoma (NHL…